News Items

The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a collaborative Phase 0/2 trial of niraparib, supported by GSK, in patients with newly diagnosed glioblastoma with unmethylated MGMT.

The Ivy Brain Tumor Center announced the first patient has been treated in a novel Phase 0/1 clinical trial of BDTX-1535, an experimental drug targeting oncogenic EGFR (epidermal growth factor receptor) mutations in patients with recurrent high-grade glioma.

In a feature by FOX10 News, Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, discussed the impactful support from the Arizona Diamondbacks. Their ongoing contributions are crucial in advancing Dr. Sanai's leading-edge research, particularly following their latest donation in memory of Nicole Hazen. This robust partnership underscores significant progress in brain tumor treatment, positioning the Ivy Center at the forefront of brain cancer care.

Outsourcing Pharma recently spotlighted the Ivy Center's groundbreaking clinical trial on AZD1390 for recurrent glioblastoma patients. The Ivy Center unveiled promising initial results, indicating that AZD1390 may act as a potent radio-sensitizer in human glioblastoma cases. This discovery marks the first instance where AZD1390's potential efficacy in enhancing radiation therapy for glioblastoma has been documented in humans. These results highlight the Ivy Center's commitment to pioneering advancements in glioblastoma treatment.

The Ivy Brain Tumor Center announced initial results from a Phase 0/1 clinical trial of the Ataxia telangiectasia mutated (ATM) kinase inhibitor AZD1390 in recurrent glioblastoma in combination with radiation therapy.

Dr. Yoshie Umemura, Chief Medical Officer at the Ivy Center, was highlighted in an episode of the Arizona Physician Podcast. During the discussion, Dr. Umemura shared insights into her motivation for pursuing a career in neuro-oncology, her reasons for joining the Ivy Center, and her strategic plans to advance the clinical trials program. Her efforts focus on pioneering new treatments for brain cancer, including glioblastoma, through innovative research and patient care.

The Head for the Cure Foundation and the Ivy Center joined forces to talk about the impact the Head for the Cure 5K makes in the brain tumor community. Dr. Shwetal Mehta, deputy director of the Ivy Brain Tumor Center, and Matt Anthony, Head for the Cure’s founder, talked about how funds raised at the walk/run go toward cutting-edge research at the Ivy Center.

The Ivy Center was featured on an episode of "Arizona & Me," a program that showcases local organizations making significant impacts in the community. During the episode, Ivy Center Director Dr. Nader Sanai discussed the origins of the Ivy Center and its dedicated mission to find a cure for the most aggressive brain tumors. Nurse Navigator Jacki Garcia detailed the patient experience, from diagnosis through treatment and every step of their journey.

August 25th marked five years since our nation lost Senator John McCain to a deadly glioblastoma brain tumor. The Ivy Brain Tumor Center honors Senator McCain and all those affected by this devastating disease by remaining committed to our mission to find a cure for patients with brain tumors. Andy McCain, son of John McCain and avid supporter of the Ivy Center, appeared on 12News to talk about his father and how the family remembers him.

In memory of Senator John McCain, Andy McCain, a board member at the Ivy Brain Tumor Center, carries on the fight against brain cancer. Led by Dr. Nader Sanai, the center pioneers innovative clinical trials, inspired by survivors like Jenn Ortiz. AZ Family highlights the efforts of the Ivy Center's efforts to find a cure the progress that has been made in the landscape of brain cancer treatment.